<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="604">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153291</url>
  </required_header>
  <id_info>
    <org_study_id>00001532</org_study_id>
    <nct_id>NCT05153291</nct_id>
  </id_info>
  <brief_title>Electrically Guided Bachmann's Bundle Pacing With Potential Antiarrhythmic Benefits</brief_title>
  <official_title>Electrically Guided Bachmann's Bundle Pacing: A Lead Placement Strategy With Potential Antiarrhythmic Benefits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite identification of optimal ventricular pacing sites, which not only avoid&#xD;
      dyssynchronous activation but can restore ventricular synchrony, optimal atrial pacing sites&#xD;
      have not yet been identified. Specialized conduction tracts do not exist in the atria as they&#xD;
      do in the ventricle. Activating the atria in a manner that preserves or improves interatrial&#xD;
      synchrony may provide clinical benefit based on recent data. Prior site-selective right&#xD;
      atrial septal pacing (RAS) pacing studies relied on non-specific fluoroscopic guidance during&#xD;
      lead placement. These studies were limited by the lack of an electrogram target and&#xD;
      electrical measures of successful atrial resynchronization. The goal of this study is to&#xD;
      prospectively evaluate Bachmann's bundle lead placement guided by fluoroscopy and electrical&#xD;
      markers (an endocardial electrogram target and paced P-wave criteria) and determine its&#xD;
      anti-arrhythmic efficacy compared with right atrial appendage (RAA) pacing. Patients&#xD;
      presenting for pacemaker placement with an indication for an atrial lead are randomized to&#xD;
      either electrically-guided BB lead placement or RAA lead placement and then followed for 15&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial arrhythmia burden from pacemaker counters</measure>
    <time_frame>Over 15 month follow up</time_frame>
    <description>Derived from pacemaker counters and expressed as the average percentage of time per day in atrial fibrillation/tachycardia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in P-wave duration from sinus P-wave to paced P-wave in Bachmann's bundle and right atrial appendage lead groups</measure>
    <time_frame>At implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial lead procedure time</measure>
    <time_frame>At implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial lead fluoroscopy time</measure>
    <time_frame>At implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial lead capture threshold (Volts)</measure>
    <time_frame>Over 15 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial lead sensing threshold (millivolts)</measure>
    <time_frame>Over 15 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial lead impedance threshold (Ohms)</measure>
    <time_frame>Over 15 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Severity Scale</measure>
    <time_frame>Over 15 month follow up</time_frame>
    <description>Change in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D survey</measure>
    <time_frame>Over 15 month follow up</time_frame>
    <description>Change in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization or urgent outpatient visit for atrial fibrillation</measure>
    <time_frame>Within 15 months follow-up post pacemaker</time_frame>
    <description>heart failure, or cerebrovascular accident, new start or up-titration of medications for the primary diagnosis of atrial fibrillation, which will be presented individually and as a composite outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization or urgent outpatient visit for heart failure</measure>
    <time_frame>Within 15 months follow-up post pacemaker</time_frame>
    <description>or cerebrovascular accident, new start or up-titration of medications for the primary diagnosis of atrial fibrillation, which will be presented individually and as a composite outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident</measure>
    <time_frame>Within 15 months follow-up post pacemaker</time_frame>
    <description>new start or up-titration of medications for the primary diagnosis of atrial fibrillation, which will be presented individually and as a composite outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New start or up-titration of medications for the primary diagnosis of atrial fibrillation</measure>
    <time_frame>Within 15 months follow-up post pacemaker</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Bachmann's bundle area lead</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lead placement in Bachmann's bundle area</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Right atrial appendage lead</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lead placement in the right atrial appendage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial lead position</intervention_name>
    <description>Patients presenting with indications for an atrial lead are randomized to one of these two atrial lead positions</description>
    <arm_group_label>Bachmann's bundle area lead</arm_group_label>
    <arm_group_label>Right atrial appendage lead</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is &gt;18 years old&#xD;
&#xD;
          -  Subject is referred for permanent pacemaker implantation with an indication for an&#xD;
             atrial lead&#xD;
&#xD;
          -  Subject has either paroxysmal atrial fibrillation or baseline intra-atrial conduction&#xD;
             delay (P-wave duration &gt;120ms on a 12-lead ECG)&#xD;
&#xD;
          -  Subject is expected to remain available for standard-of-care pacemaker follow-up&#xD;
             visits and study questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has permanent atrial fibrillation or is in atrial fibrillation in the&#xD;
             pre-operative area prior to the procedure (inability to assess paced P-wave&#xD;
             morphology)&#xD;
&#xD;
          -  Subject has resting spontaneous sinus rate &gt;85 beats-per-minute&#xD;
&#xD;
          -  Subject has left ventricular ejection fraction &lt;45%&#xD;
&#xD;
          -  Subject is unable or unwilling to complete baseline or follow up quality of life&#xD;
             questionnaires&#xD;
&#xD;
          -  Subject is currently enrolled in a potentially confounding trial&#xD;
&#xD;
          -  Subject is pregnant&#xD;
&#xD;
          -  Subject's anticipated life expectancy is less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaret Infeld, MD, MS</last_name>
    <phone>8028472763</phone>
    <email>margaret.infeld@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Infeld, MD, MS</last_name>
      <phone>802-847-2763</phone>
      <email>margaret.infeld@uvmhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 27, 2021</last_update_submitted>
  <last_update_submitted_qc>November 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Margaret Infeld</investigator_full_name>
    <investigator_title>Cardiac Electrophysiology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified data upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

